Aberrant rac1-mineralocorticoid receptor pathways in salt-sensitive hypertension

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 12, 2013, Pages 929-936

  Kawarazaki, Wakako ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Aldosterone; Aldosterone releasing factors; Kidney; Metabolic syndrome; Mineralocorticoid receptor; Obesity; Rac1; Salt sensitivity of blood pressure; Salt sensitive hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; CYCLIC AMP DEPENDENT PROTEIN KINASE; ESTROGEN RECEPTOR; GLUCOCORTICOID; INTERLEUKIN 6; MINERALOCORTICOID RECEPTOR; NORADRENALIN; PROTEIN CDC42; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADRENAL GLAND; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ALDOSTERONE URINE LEVEL; BLOOD PRESSURE REGULATION; CONGENITAL NEPHROTIC SYNDROME; DAHL SALT SENSITIVE RAT; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INTRACELLULAR SIGNALING; KIDNEY INJURY; META ANALYSIS (TOPIC); NEGATIVE FEEDBACK; NONHUMAN; OBESITY; OXIDATIVE STRESS; PODOCYTE; PROTEINURIA; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SALT LOADING; SALT SENSITIVE HYPERTENSION; SODIUM ABSORPTION; SODIUM EXCRETION; SODIUM RETENTION;

ALDOSTERONE; ALDOSTERONE-RELEASING FACTORS; KIDNEY; METABOLIC SYNDROME; MINERALOCORTICOID RECEPTOR; OBESITY; RAC1; SALT SENSITIVITY OF BLOOD PRESSURE; SALT-SENSITIVE HYPERTENSION;

ALDOSTERONE; ANIMALS; HUMANS; HYPERTENSION; KIDNEY; METABOLIC SYNDROME X; RAC1 GTP-BINDING PROTEIN; RATS; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SODIUM; SODIUM CHLORIDE, DIETARY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84888019373     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12177     Document Type: Review

References (72)

1. Miall WE, Oldham PD. The hereditary factor in arterial blood-pressure. BMJ 1963; 1: 75-80.
2. Fujita T, Henry WL, Bartter FC, Lake CR, Delea CS. Factors influencing blood pressure in salt-sensitive patients with hypertension. Am. J. Med. 1980; 69: 334-44.
3. Penner SB, Campbell NR, Chockalingam A, Zarnke K, Van Vliet B. Dietary sodium and cardiovascular outcomes: A rational approach. Can. J. Cardiol. 2007; 23: 567-72.
4. Heerspink HJL, Navis G, Ritz E. Salt intake in kidney disease: A missed therapeutic opportunity? Nephrol. Dial. Transplant. 2012; 27: 3435-42.
5. Luft FC, Weinberger MH. Heterogeneous responses to changes in dietary salt intake: The salt-sensitivity paradigm. Am. J. Clin. Nutr. 1997; 65(Suppl.): S612-7.
6. Rocchini AP, Key J, Bondie D et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N. Engl. J. Med. 1989; 321: 580-5.
7. Chen J, Gu D, Huang J et al. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: A dietary intervention study. Lancet 2009; 373: 829-35.
8. Bentley-Lewis R, Adler GK, Perlstein T et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J. Clin. Endocrinol. Metab. 2007; 92: 4472-5.
9. Engeli S, Böhnke J, Gorzelniak K et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-62.
10. Kidambi S, Kotchen JM, Grim CE et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007; 49: 704-11.
11. Shibata S, Nagase M, Yoshida S et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease. Nat. Med. 2008; 14: 1370-6.
12. Shibata S, Mu S, Kawarazaki H et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J. Clin. Invest. 2011; 121: 3233-43.
13. Guyton AC. Kidneys and fluids in pressure regulation. Small Volume but large pressure changes. Hypertension 1992; 19(Suppl. I): I-2-8.
14. Dahl LK, Heine M, Thompson K. Genetic influence of the kidneys on blood pressure. Evidence from chronic renal homografts in rats with opposite predispositions to hypertension. Circ. Res. 1974; 40: 94-101.
15. Crowley SD, Gurley SB, Herrera MJ et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc. Natl Acad. Sci. USA 2006; 103: 17 985-90.
16. 1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab. 2011; 13: 469-75.
17. Funder JW. Mineralocorticoid receptors: Distribution and activation. Heart Fail. Rev. 2005; 10: 15-22.
18. Mihailidou AS, Le Loan TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009; 54: 1306-12.
19. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J. Clin. Endocrinol. Metab. 2004; 89: 2736-40.
20. McCurley A, Pires PW, Bender SB et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat. Med. 2012; 18: 1429-33.
21. Gomez-Sanchez EP. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology 1986; 118: 819-23.
22. Gómez Sánchez EP, Venkataraman MT, Thwaites D, Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am. J. Physiol. 1990; 258: E649-53.
23. Gomez Sanchez EP. Dose-response studies of intracerebroventricular infusion of aldosterone in sensitized and non-sensitized rats. J. Hypertens. 1988; 6: 437-42.
24. Huang BS, White RA, Jeng AY, Leenen FH. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in dahl salt-sensitive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009; 296: R994-1000.
25. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol. Cell. Endocrinol. 2012; 350: 256-65.
26. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009; 54: 537-43.
27. Usher MG, Duan SZ, Ivaschenko CY et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 2010; 120: 3350-64.
28. Francis J, Weiss RM, Wei SG et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am. J. Physiol. Heart Circ. Physiol. 2001; 281: H2241-51.
29. Zhang ZH, Kang YM, Yu Y et al. 11β-Hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation. Hypertension 2006; 48: 127-33.
30. Mu S, Shimosawa T, Ogura S et al. Epigenetic modulation of the renal β-adrenergic-wnk4 pathway in salt-sensitive hypertension. Nat. Med. 2011; 17: 573-80.
31. Nagase M, Yoshida S, Shibata S et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: Possible contribution of fat-derived factors. J. Am. Soc. Nephrol. 2006; 17: 3438-46.
32. Rossi GP, Belfiore A, Bernini G et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J. Clin. Endocrinol. Metab. 2008; 93: 2566-71.
33. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43: 41-7.
34. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl Acad. Sci. USA 2003; 100: 14 211-6.
35. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43: 358-63.
36. Wong GW, Wang J, Hug C, Tsao TS, Lodish HF. A family of acrp30/adiponectin structural and functional paralogs. Proc. Natl Acad. Sci. USA 2004; 101: 103 02-7.
37. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: Role of oxidative stress. Hypertension 2007; 50: 877-83.
38. Matsui H, Ando K, Kawarazaki H et al. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 2008; 52: 287-94.
39. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone. Roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-64.
40. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-8.
41. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell. Cardiol. 1993; 25: 563-75.
42. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47: 1084-93.
43. Weigel NL, Moore NL. Kinases and protein phosphorylation as regulators of steroid hormone action. Nucl. Recept. Signal. 2007; 5: e005.
44. Yokota K, Shibata H, Kurihara I et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J. Biol. Chem. 2007; 282: 1998-2010.
45. Krug AW, Allenhöfer L, Monticone R et al. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 2010; 55: 1476-83.
46. Denner LA, Weigel NL, Maxwell BL, Schrader WT, O'Malley BW. Regulation of progesterone receptor-mediated transcription by phosphorylation. Science 1990; 250: 1740-3.
47. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: New insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 2008; 9: 690-701.
48. Welsh GI, Saleem MA. The podocyte cytoskeleton. Key to a functioning glomerulus in health and disease. Nat. Rev. Nephrol. 2012; 8: 14-21.
49. Mundel P, Reiser J. Proteinuria. An enzymatic disease of the podocyte? Kidney Int. 2010; 77: 571-80.
50. Lezoualc'h F, Métrich M, Hmitou I, Duquesnes N, Morel E. Small GTP-binding proteins and their regulators in cardiac hypertrophy. J. Mol. Cell. Cardiol. 2008; 44: 623-32.
51. Frost JA, Swantek JL, Stippec S, Yin MJ, Gaynor R, Cobb MH. Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. J. Biol. Chem. 2000; 275: 19 693-9.
52. Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH, Guan KL. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 2000; 290: 144-7.
53. Kawashima T, Bao YC, Nomura Y et al. Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors. J. Cell Biol. 2006; 175: 937-46.
54. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell 2008; 133: 340-53.
55. Barone I, Brusco L, Gu G et al. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. J. Natl Cancer Inst. 2011; 103: 538-52.
56. Nagase M, Ayuzawa N, Kawarazaki W et al. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: Role of small GTPase Rac1. Hypertension 2012; 59: 500-6.
57. Papaharalambus C, Sajjad W, Syed A et al. Tumor necrosis factor alpha stimulation of Rac1 activity. Role of isoprenylcysteine carboxylmethyltransferase. J. Biol. Chem. 2005; 280: 18 790-6.
58. Takemoto M, Node K, Nakagami H et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 2001; 108: 1429-37.
59. Nishida M, Tanabe S, Maruyama Y et al. G alpha 12/13- and reactive oxygen species-dependent activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J. Biol. Chem. 2005; 280: 18434-41.
60. Schmitz U, Thömmes K, Beier I et al. Angiotensin II-induced stimulation of p21-activated kinase and c-Jun NH2-terminal kinase is mediated by Rac1 and Nck. J. Biol. Chem. 2001; 276: 22 003-10.
61. Lin S, Li D, Jia J, Zheng Z, Jia Z, Shang W. Spironolactone ameliorates podocytic adhesive capacity via restoring integrin alpha 3 expression in streptozotocin-induced diabetic rats. J. Renin Angiotensin Aldosterone Syst. 2010; 11: 149-57.
62. Aikawa R, Nagai T, Tanaka M et al. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem. Biophys. Res. Commun. 2001; 289: 901-7.
63. Akilesh S, Suleiman H, Yu H et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J. Clin. Invest. 2011; 121: 4127-37.
64. Gupta IR, Baldwin C, Auguste D et al. ARHGDIA: A novel gene implicated in nephrotic syndrome. J. Med. Genet. 2013; 50: 330-8.
65. Gee HY, Saisawat P, Ashraf S et al. ARHGDIA mutations cause nephrotic syndrome via defective Rho GTPase signaling. J. Clin. Invest. 2013; 123: 3243-53.
66. Kobori H, Nishiyama A, Abe Y, Navar LG. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 2003; 41: 592-7.
67. Kawarazaki W, Nagase M, Yoshida S et al. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J. Am. Soc. Nephrol. 2012; 23: 997-1007.
68. Fukamizu A, Sugimura K, Takimoto E et al. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J. Biol. Chem. 1993; 268: 11 617-21.
69. Oishi T, Date S, Shimamoto Y et al. A nuclear receptor, hepatocyte nuclear factor 4, differently contributes to the human and mouse angiotensinogen promoter activities. J. Recept. Signal Transduct. Res. 2010; 30: 484-92.
70. Jin S, Ray RM, Johnson LR. TNF-alpha/cycloheximide-induced apoptosis in intestinal epithelial cells requires Rac1-regulated reactive oxygen species. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 294: G928-37.
71. Schuringa JJ, Dekker LV, Vellenga E, Kruijer W. Sequential activation of Rac-1, SEK-1/MKK-4, and protein kinase Cdelta is required for interleukin-6-induced STAT3 Ser-727 phosphorylation and transactivation. J. Biol. Chem. 2001; 276: 27709-15.
72. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc. Natl Acad. Sci. USA 2006; 103: 7432-7.